CLYM19112 / S1826 / Jonathan Friedberg
Research Question:
What is the effect of immunotherapy drugs (nivolumab or brentuximab vedotin) when
given with combination chemotherapy in treating patients with newly diagnosed stage
III or IV classic Hodgkin lymphoma?
Basic Study Information
Purpose:
This phase III trial compares immunotherapy drugs (nivolumab or brentuximab vedotin)
when given with combination chemotherapy in treating patients with newly diagnosed
stage III or IV classic Hodgkin lymphoma. Immunotherapy with monoclonal antibodies,
such as nivolumab, may help the body's immune system attack the cancer, and may interfere
with the ability of tumor cells to grow and spread. Brentuximab vedotin is a monoclonal
antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches
to cancer cells in a targeted way and delivers vedotin to kill them. Chemotherapy
drugs, such as doxorubicin, vinblastine, and dacarbazine, work in different ways to
stop the growth of cancer cells, either by killing the cells, by stopping them from
dividing, or by stopping them from spreading. The addition of nivolumab or brentuximab
vedotin to combination chemotherapy may shrink the cancer or extend the time without
disease symptoms coming back.
Location: University of Rochester Medical Center
Study Reference #: CLYM19112
Lead Researcher (Principal Investigator)
Lead Researcher:
Jonathan Friedberg, MD
Study Contact Information
Study Coordinator: Tina Bowdish
Phone: +1 585-275-9475
Email: tina_bowdish@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search